Loading clinical trials...

A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT05624944

A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment

This is an open-label pharmacokinetic study of TS-142 in patients with hepatic impairment

Lead sponsor: Taisho Pharmaceutical Co., Ltd.•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment84

Start dateDec 2022

Last updatedFeb 28, 2025

Condition

Patients with Mild or Moderate Hepatic Impairment

Locations shown

Taisho Pharmaceutical Co., Ltd selected site

Tokyo

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2025Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions